The U.S. biopharmaceutical sector is working on 465 drugs that target 10 of the most common chronic conditions among seniors, according to data published by PhRMA. The lineup includes 40 medicines for chronic obstructive pulmonary disease, 48 for heart failure, 82 for Alzheimer's, 92 for osteoarthritis and rheumatoid arthritis, and 142 for diabetes. The prospective treatments are being tested in patients or are being reviewed by the FDA.

Full Story:
PharmaTimes (U.K.)

Related Summaries